Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | OGG1 | O15527 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31573869 | 0.98 | ALDH1A1 (0.34) | ALDH1A1HTTLMNAPOLBHIF1A | |
| Tetrahydrofuran SCHEMBL4931679 | 0.87 | POLB (0.43) | ALDH1A1HTTLMNAPOLBSLC1A2 | |
| SCHEMBL12109372 | 0.82 | ALDH1A1 (0.39) | ALDH1A1HTTLMNAPOLBSLC1A2 | |
| SCHEMBL10037551 | 0.81 | POLB (0.38) | ALDH1A1HTTLMNAPOLBSLC1A2 | |
| SCHEMBL12107536 | 0.80 | CYP1A2 (0.43) | ALDH1A1HTTLMNAPOLBSLC1A2 | |
| SCHEMBL10037495 | 0.77 | SLC1A2 (0.42) | ALDH1A1HTTLMNAHIF1ASLC1A2 | |
| SCHEMBL27253677 | 0.77 | KMT2A (0.49) | ALDH1A1HTTLMNAHIF1AMAPT | |
| SCHEMBL2347972 | 0.77 | KMT2A (0.49) | ALDH1A1HTTLMNAHIF1AMAPT | |
| SCHEMBL17841877 | 0.77 | TERT (0.40) | HTTSLC1A2SMN1; SMN2GAA | |
| SCHEMBL30269173 | 0.77 | TERT (0.40) | HTTSLC1A2SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2734239-A2 | LONG ACTING LUTEINIZING HORMONE (LH) COMPOUND | Arts Biologics A/S (DK) | 2014-05-28 | — | — | EP | claimed |
| WO-2013010840-A2 | LONG ACTING BIOLOGICALLY ACTIVE LUTEINIZING HORMONE (LH) COMPOUND | ARTS BIOLOGICS A/S (DK) | 2013-01-24 | — | — | WO | claimed |
| US-20110142762-A1 | Conjugates for medical imaging comprising carrier, targeting moiety and a contrast agent | NOVOZYMES BIOPHARMA DK A/S (DK) | 2011-06-16 | — | — | US | claimed |
| EP-1605979-B1 | CONJUGATES FOR MEDICAL IMAGING COMPRISING CARRIER, TARGETING MOIETY AND A CONTRAST AGENT | UPPERTON LTD (GB) | 2008-10-22 | — | — | EP | claimed |
| JP-2006518727-A | — | — | 2006-08-17 | — | — | JP | claimed |
| US-20060171892-A1 | Conjugates for medical imaging comprising carrier, targetting moiety and a contrast agent | NOVOZYMES BIOPHARMA UK LIMITED (GB) | 2006-08-03 | — | — | US | claimed |
| EP-1605979-A1 | CONJUGATES FOR MEDICAL IMAGING COMPRISING CARRIER, TARGETING MOIETY AND A CONTRAST AGENT | Upperton Limited (GB) | 2005-12-21 | — | — | EP | claimed |
| WO-2004071536-A1 | CONJUGATES FOR MEDICAL IMAGING COMPRISING CARRIER, TARGETING MOIETY AND A CONTRAST AGENT | UPPERTON LIMITED (GB) | 2004-08-26 | — | — | WO | claimed |
| EP-4687843-A1 | FORMULATIONS AND USES THEREOF | Sartorius Albumedix Limited (GB) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025226722-A1 | DNA ANTIBODY AND IMMUNOGEN CONSTRUCTS FOR USE IN METHODS OF TREATING AND PREVENTING INFLUENZA | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2025-10-30 | — | — | WO | disclosed |
| US-12448419-B2 | Methods and compositions for treating inflammation | UTI LIMITED PARTNERSHIP (CA) | 2025-10-21 | — | — | US | disclosed |
| WO-2025217530-A1 | HIV-1 IMMUNOGENS AND METHODS OF USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250312474-A1 | ANTHRACYCLINS AND CONJUGATES THEREOF | SYNAFFIX B.V. (NL) | 2025-10-09 | — | — | US | disclosed |
| EP-3291832-B1 | NANOPARTICLE COMPOSITIONS FOR SUSTAINED THERAPY | UTI LP (CA) | 2025-09-03 | — | — | EP | disclosed |
| EP-1605979-A1 | CONJUGATES FOR MEDICAL IMAGING COMPRISING CARRIER, TARGETING MOIETY AND A CONTRAST AGENT | Upperton Limited (GB) | 2005-12-21 | — | — | EP | disclosed |
| US-20050064604-A1 | Assay based on doped nanoparticles | BAYER TECHNOLOGY SERVICES GMBH | 2005-03-24 | — | — | US | disclosed |
| WO-2004096944-A1 | CORE/SHELL NANOPARTICLES SUITABLE FOR (F)RET-ASSAYS | NANOSOLUTIONS GMBH (DE) | 2004-11-11 | — | — | WO | disclosed |
| EP-1473347-A1 | Core/shell nanoparticles suitable for (F) RET-assays | Nanosolutions GmbH (DE) | 2004-11-03 | — | — | EP | disclosed |
| WO-2004071536-A1 | CONJUGATES FOR MEDICAL IMAGING COMPRISING CARRIER, TARGETING MOIETY AND A CONTRAST AGENT | UPPERTON LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
| US-20040014060-A1 | Doped nanoparticles as biolabels | BAYER AKTIENGESELLSCHAFT (DE) | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312474-A1 | ANTHRACYCLINS AND CONJUGATES THEREOF | ANTXR2, NCL, DUT | ALDH1A1 3914/4885HTT 2112/4885LMNA 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.